A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses.
Ontology highlight
ABSTRACT: Graphical abstractCyclic peptide C25 targeting LAG-3 was developed by phage display bio-panning. C25 binds to LAG-3 and is capable of preventing the binding of LAG-3 to HLA-DR. C25 exhibits significant anti-tumor activity dependent on CD8+ T cells activation. Surprisingly, it can also lead to the reduction of Tregs in tumor microenvironment.Image 1
SUBMITTER: Zhai W
PROVIDER: S-EPMC7332792 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA